🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "major milestone" in the effort against superbug strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Treatment Options Secure Authorization

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is also used to treat UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

As per results published in a major medical journal, zoliflodacin eradicated the vast majority of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which involves two antibiotics. The trial enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. Having a one-pill regimen like this is described as a "game-changer" for gonorrhoea control. This is deemed crucial to lessen the impact of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea globally.